GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Revenue per Share

BRTX (BioRestorative Therapies) Revenue per Share : $0.05 (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Revenue per Share?

BioRestorative Therapies's revenue per share for the three months ended in Sep. 2024 was $0.03. BioRestorative Therapies's revenue per share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.05.

Warning Sign:

BioRestorative Therapies Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue Per Share Growth Rate of BioRestorative Therapies was 69.00% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -31.30% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -77.30% per year. During the past 10 years, the average Revenue Per Share Growth Rate was -64.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for BioRestorative Therapies's Revenue per Share or its related term are showing as below:

BRTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -89.8   Med: -61.1   Max: 80.7
Current: -31.3

During the past 13 years, BioRestorative Therapies's highest 3-Year average Revenue Per Share Growth Rate was 80.70% per year. The lowest was -89.80% per year. And the median was -61.10% per year.

BRTX's 3-Year Revenue Growth Rate is ranked worse than
84.32% of 759 companies
in the Biotechnology industry
Industry Median: 3.5 vs BRTX: -31.30

BioRestorative Therapies Revenue per Share Historical Data

The historical data trend for BioRestorative Therapies's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Revenue per Share Chart

BioRestorative Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.84 0.11 0.04 0.03 0.04

BioRestorative Therapies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.01 0.01 0.03

Competitive Comparison of BioRestorative Therapies's Revenue per Share

For the Biotechnology subindustry, BioRestorative Therapies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's PS Ratio distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's PS Ratio falls into.



BioRestorative Therapies Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

BioRestorative Therapies's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=0.146/4.218
=0.03

BioRestorative Therapies's Revenue Per Share for the quarter that ended in Sep. 2024 is calculated as

Revenue Per Share (Q: Sep. 2024 )=Revenue (Q: Sep. 2024 )/Shares Outstanding (Diluted Average) (Q: Sep. 2024 )
=0.234/8.121
=0.03

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioRestorative Therapies  (NAS:BRTX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


BioRestorative Therapies Revenue per Share Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Executives
Dale Broadrick 10 percent owner 3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Francisco Silva director, 10 percent owner, officer: VP of Research and Development STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Lance Alstodt director, 10 percent owner, officer: President, CEO, COB BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert Eugene Kristal officer: Chief Financial Officer 4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams director C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov director 4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb director, 10 percent owner, officer: CEO and Chairman of the Board STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna director 69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov director 8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi officer: VP, Quality and Compliance C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein officer: SVP, Planning and Business Dev 167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais director 230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust 10 percent owner VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000